CRYPU - Clinical: Cryptococcus Antigen, Urine

Test Catalog

Test Name

Test ID: CRYPU    
Cryptococcus Antigen, Urine

Useful For Suggests clinical disorders or settings where the test may be helpful

Aiding in the diagnosis of cryptococcosis

Clinical Information Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test

Cryptococcosis is an invasive fungal infection caused by Cryptococcus neoformans. The organism has been isolated from several sites in nature, particularly weathered pigeon droppings.


Infection is usually acquired via the pulmonary route. Patients are often unaware of any exposure history. Approximately half of the patients with symptomatic disease have a predisposing immunosuppressive condition such as AIDS, steroid therapy, lymphoma, or sarcoidosis. Symptoms may include fever, headache, dizziness, ataxia, somnolence, and cough.


In addition to the lungs, cryptococcal infections frequently involve the central nervous system (CNS), particularly in patients infected with HIV. Mortality in CNS cryptococcosis may approach 25% despite antibiotic therapy. Untreated CNS cryptococcosis is invariably fatal. Disseminated disease may affect any organ system and usually occurs in immunosuppressed individuals.

Reference Values Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.


Interpretation Provides information to assist in interpretation of the test results

The presence of cryptococcal antigen in any body fluid is indicative of cryptococcosis.


Higher titers appear to correlate with more severe infections. Declining titers in urine or serum may indicate regression of infection or response to therapy. However, monitoring titers to cryptococcal antigen should not be used as a test of cure, as low level titers may persist for extended periods of time following appropriate therapy and the resolution of infection.


In addition to testing for cryptococcal antigen, patients with presumed disease due to Cryptococcus neoformans should have clinical specimens (eg, bronchoalveolar lavage fluid) submitted for routine smear and fungal culture.

Cautions Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances

A negative result does not preclude the diagnosis of cryptococcosis, particularly if only a single specimen has been tested and the patient shows symptoms consistent with cryptococcosis.


Patients having trichosporonosis may yield false-positive results.


Rheumatoid factor may produce false-positive results.

Supportive Data

Thirty analyte-negative urine specimens were spiked with a positive control specimen (purified cryptococcal antigen derived from a culture isolate of Cryptococcus neoformans to yield a desired endpoint titer of 1:16 (10 specimens), 1:64 (10 specimens) or 1:512 (10 specimens). These specimens were then tested by the Cryptococcal Antigen Latex Agglutination System (CALAS; Meridian Bioscience, Cincinnati, OH) and all samples yielded the expected endpoint titer (one, 2-fold serial dilution).


To assess analytical specificity, urine specimens previously shown to be positive for Histoplasma (n=6) or Blastomyces (n=1) antigen were tested by the CALAS assay. In addition, analyte-negative urine samples (n=16) spiked with Aspergillus antigen control material were tested. All specimens (23/23=100%) containing potentially cross-reactive fungal antigen were negative by the CALAS assay.

Clinical Reference Recommendations for in-depth reading of a clinical nature

Hazen KC, Howell SA: Candida, Cryptococcus, and other Yeasts of Medical Importance. In Manual of Clinical Microbiology. Ninth edition. Edited by PR Murray. Washington, DC, ASM Press, 2007, pp 1762-1788